Metsera (NASDAQ:MTSR) Posts Earnings Results

Key Points

• Metsera (NASDAQ:MTSR) reported an earnings per share (EPS) of ($0.66) for the quarter, indicating a loss.
• Following the earnings announcement, MTSR shares fell 2.6%, trading at $39.43 with over 1.5 million shares exchanged.
• Analysts are optimistic about Metsera, giving it a consensus “Buy” rating with an average target price of $55.00.

Metsera (NASDAQ:MTSR - Get Free Report) posted its earnings results on Monday. The company reported ($0.66) EPS for the quarter, Zacks reports.

Metsera Trading Down 2.6%

Shares of MTSR traded down $1.04 during midday trading on Monday, reaching $39.43. 1,500,346 shares of the stock were exchanged, compared to its average volume of 907,791. Metsera has a 52 week low of $12.30 and a 52 week high of $47.40. The firm has a 50 day moving average price of $31.84.

Institutional Trading of Metsera

Several institutional investors and hedge funds have recently made changes to their positions in MTSR. Strs Ohio bought a new position in Metsera during the 1st quarter worth about $76,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Metsera during the first quarter valued at approximately $248,000. Finally, Goldman Sachs Group Inc. purchased a new position in Metsera during the first quarter valued at approximately $568,000.

Wall Street Analyst Weigh In

MTSR has been the subject of several recent analyst reports. Wells Fargo & Company initiated coverage on Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 target price for the company. Guggenheim boosted their target price on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $55.00.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.